DiscoverWolverHeme Happy HourCast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma
Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma

Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma

Update: 2024-11-08
Share

Description

In this episode, Bernie and Anthony are joined by two special guest expert hematologists:


Dr. David Russler-Germain


Dr. Tycel Phillips


We discuss recent updates in the treatment of upfront Classical Hodgkin Lymphoma, including whether the SWOG S1826 and HD21 trials change practice! Will it be a landslide victory for nivolumab? Is brentuximab fired?


Stay tuned to find out!

Comments 
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma

Cast your vote! Nivolumab vs. Brentuximab for Classical Hodgkin Lymphoma

Bernard Marini, Anthony Perissinotti, et al.